Bristol-Myers Squibb Company vs Intel Corporation: Strategic Comparison

This in-depth comparison examines Bristol-Myers Squibb Company and Intel Corporation across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Bristol-Myers Squibb Company on its own, evaluating Intel Corporation, or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Bristol-Myers Squibb Company and Intel Corporation is widest.

On the headline numbers, Bristol-Myers Squibb Company reports annual revenue of $48.2B against $52.9B for Intel Corporation, while their respective market capitalizations stand at $127.5B and $639.9B. Both Bristol-Myers Squibb Company and Intel Corporation are headquartered in United States, so they compete in a shared home market and regulatory environment.

Bristol-Myers Squibb Company: Bristol Myers Squibb (BMS) is a U.S. biopharmaceutical company headquartered in Princeton, New Jersey, and listed on the New York Stock Exchange as BMY. It develops and sells prescription medicines for cancer, blood disorders, immune diseases, heart disease and schizophrenia. Its best-known products are Eliquis, the anticoagulant it sells with Pfizer, and Opdivo, a PD-1 checkpoint inhibitor. With $48.2 billion of 2025 revenue and a market value of about $127 billion at the end of September 2026, it is one of the largest U.S. drugmakers by sales.

Intel Corporation: Intel was founded in 1968 by Robert Noyce and Gordon Moore and became the defining PC chip company through the x86 architecture, the 'Intel Inside' brand, and its partnership with Microsoft. It missed the smartphone shift, suffered years of 10nm and 7nm delays, and lost Apple's Mac business to Apple silicon in 2020. Pat Gelsinger's IDM 2.0 plan (2021-2024) rebuilt the process roadmap at high cost. Lip-Bu Tan, CEO since March 2025, has focused on cost cuts, customer focus, and new capital from the U.S. government, Nvidia, and SoftBank.

Bristol-Myers Squibb Company and Intel Corporation pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Bristol-Myers Squibb Company and Intel Corporation.

Bristol-Myers Squibb Company business model: BMS discovers, licenses or buys drug candidates, takes them through clinical trials, and sells approved medicines under patent protection to wholesalers, specialty pharmacies and hospitals. Net product sales were $46.8 billion of the $48.2 billion total in 2025; alliance, royalty and other revenues made up the remaining $1.4 billion, including royalties from Merck on Winrevair. Eliquis is developed and sold with Pfizer, which shares its costs and profits. About 69 percent of 2025 revenue came from the United States, so U.S. pricing policy matters more to BMS than to most European rivals. Because every patent runs out, the model depends on replacing revenue: BMS paid $74 billion for Celgene in 2019, $13.1 billion for MyoKardia in 2020 and about $23 billion for Karuna, Mirati and RayzeBio in early 2024.

Intel Corporation business model: Intel is an integrated device manufacturer (IDM): it designs chips and runs its own fabs in Oregon, Arizona, New Mexico, Ireland, and Israel. Since 2024 it reports two halves. Intel Products (client CPUs, Xeon data-center CPUs, AI accelerators) sells to OEMs, hyperscalers, and enterprises. Intel Foundry manufactures wafers and packages for Intel Products and for external customers, competing with TSMC and Samsung. Intel also owns a majority of Mobileye (ADAS chips) and kept a 49% stake in Altera after selling 51% to Silver Lake in September 2025.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Bristol-Myers Squibb Company stack up against those of Intel Corporation.

Bristol-Myers Squibb Company competitive advantage: BMS's advantage is its expertise in oncology and its large commercial and regulatory organization. Developing a cancer immunotherapy is complex, and winning approval from regulators and getting doctors to prescribe it requires an established global sales and regulatory team. Smaller biotech companies often lack that infrastructure, so they partner with or sell to a company like BMS to bring their discoveries to market.

Intel Corporation competitive advantage: Intel's advantages are the installed base of x86 software, deep OEM and enterprise relationships, leading-edge U.S. fabs, and advanced packaging (EMIB, Foveros) that AI chip designers increasingly need. Its role as the main American maker of leading-edge logic chips also brings policy support: the U.S. government became its largest shareholder in August 2025.

Future prospects matter as much as current results. The growth strategies below explain how Bristol-Myers Squibb Company and Intel Corporation each plan to expand from here.

Bristol-Myers Squibb Company growth strategy: BMS is pursuing growth on three fronts. First, scaling the Growth Portfolio (Opdivo Qvantig, Reblozyl, Camzyos, Breyanzi, Opdualag, Cobenfy and others), which rose 17 percent to $26.4 billion in 2025 and 15 percent to $7.56 billion in the second quarter of 2026. Second, buying and licensing late-stage science: Mirati ($4.8 billion plus a contingent value right of up to $1 billion), RayzeBio ($4.1 billion) and Karuna ($14 billion) closed in early 2024; a June 2025 deal with BioNTech for the bispecific BNT327 carried $1.5 billion upfront and up to $11.1 billion in total; and Orbital Therapeutics was bought for $1.5 billion in October 2025 for in vivo CAR-T in autoimmune disease. Third, cost cuts: a $1.5 billion savings program announced in 2024 was extended in 2025 with a further $2 billion targeted by the end of 2027.

Intel Corporation growth strategy: Under Lip-Bu Tan, Intel has cut layers and headcount, slowed some fab projects such as Ohio, and tied foundry spending to committed customer demand. Growth bets for 2026-2027 are Xeon CPUs for AI servers (DCAI revenue rose 59% year over year in Q2 2026), Panther Lake AI PC processors on Intel 18A, advanced packaging for third-party AI chips, custom x86 parts co-developed with Nvidia, and winning external customers for the 14A node.

A closer look at the financial trajectory of Bristol-Myers Squibb Company and Intel Corporation rounds out the comparison.

Bristol-Myers Squibb Company: Revenue grew from $19.4 billion in 2016 to $42.5 billion in 2020 as Celgene's sales were added, and has stayed between $45.0 billion and $48.3 billion since 2021. Net earnings are far less stable because BMS expenses acquired in-process R&D: the $11.4 billion MyoKardia charge produced a $9.0 billion net loss in 2020, and the Karuna charge produced an $8.9 billion loss in 2024. Cash generation is steadier, with free cash flow of about $12.8 billion in 2025. That cash funds a dividend raised for a 17th straight year in February 2026, to $0.63 a quarter, and debt reduction, from $51.2 billion at the end of 2024 to $47.2 billion a year later. On July 30, 2026 BMS raised its 2026 revenue guidance to $49.0 to $50.0 billion, from $46.0 to $47.5 billion, after second-quarter revenue rose 6 percent to $12.97 billion.

Intel Corporation: Intel's revenue peaked at $79.0 billion in 2021 and fell to $53.1 billion in 2024, when it posted an $18.8 billion net loss driven by restructuring and impairments. FY2025 revenue was $52.9 billion with a much smaller $267 million net loss, and the year ended with $37.4 billion in cash and short-term investments. Q2 2026 revenue rose 25% to $16.1 billion with a 41.8% non-GAAP gross margin and $0.42 non-GAAP EPS. GAAP net loss for the quarter was $11.0 billion, almost all from a $12.5 billion non-cash mark-to-market charge on shares escrowed for the U.S. Department of Commerce. Intel guided Q3 2026 revenue to $15.8-16.8 billion.